Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company is focused on CapEx investments, with a Rs. 25 Crore CapEx planned for the next quarter and ongoing investments based on regulatory and strategic requirements. CapEx decisions beyond the ongoing investments will be made post-audit, indicating no immediate new fundraising plans. The discussion also highlights internal funding of expansion and R&D activities without reference to raising external capital. Overall, the company appears to be managing funded growth throug

Any current/future capex/capital investment/strategic investment?

Anwar Daud and Shyam Patro mentioned ongoing and future CapEx investments aligned with regulatory needs and strategic expansion. Next quarter CapEx investment expected around Rs. 25 Crore. CapEx is focused on debottlenecking, capacity expansion, and regulatory compliance, including preparations for ANVISA inspections in South American markets like Brazil and Mexico. There is a plan to double overall capacity in the next two years, with a 25% to 40% capacity enhancement expected in the coming couple of years. Additional CapEx decisions will be made post-audit based on future requirements. CapEx

Future growth expectations in sales/revenue/volumes?

FY'25 sales expected to reflect contributions from regulated markets filings and supplies, signaling growth potential. NIP (New Innovative Products) portfolio anticipated to expand from 4 to 7-8 by FY'25, indicating pipeline growth. Margins expected to improve to 15%-17% EBITDA if conditions remain favorable. Regulatory filings in Europe and other markets forecast 1.5 to 2 years for approvals, with rollout starting FY'25 and scaling over time. NIP and Oral Thin Film (OTF) products could contribute up to 30%-40% of overall revenues in the near term. Capacity enhancements planned at 25

Current/ Expected Orderbook/ Pending Orders?

There is a robust order list for Nutraceutical products, with several orders in hand. Some supply is pending due to currency issues in certain markets, as supplies are against advance payments. A single Nutra order from last year, worth about Rs. 20 crores, was not repeated due to currency constraints. The business saw a revenue loss of approximately Rs. 20 crores last year linked to currency issues. Supply has started for filings done in regulated markets, with agreements made and orders flowing in. NIP and ODS product orders have started contributing to business, with strong growth expected

IN US

Sale is live|00:00:00left today

Zim Laboratories LtdQ4 FY25Pharmaceuticals & Biotechnology

Zim Laboratories Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹126P/E: 75.2Market Cap: ₹526 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→FY'25 sales expected to reflect contributions from regulated markets filings and supplies, signaling growth potential.
→NIP (New Innovative Products) portfolio anticipated to expand from 4 to 7-8 by FY'25, indicating pipeline growth.
→Margins expected to improve to 15%-17% EBITDA if conditions remain favorable.
→Regulatory filings in Europe and other markets forecast 1.5 to 2 years for approvals, with rollout starting FY'25 and scaling over time.
→NIP and Oral Thin Film (OTF) products could contribute up to 30%-40% of overall revenues in the near term.
→Capacity enhancements planned at 25%-40% over the next two years, potentially doubling overall capacity, supporting volume growth.
→Despite challenges (currency issues, Red Sea crisis), easing conditions and expanding geographic footprint are expected to stabilize and improve revenue streams.
→India business and Nutraceutical segments show consistent margin improvements and growth potential.

Margin guidance

Category 1

- EBITDA margin is expected to improve from current 12%-13% to around 15%-17% if conditions are favorable (Page 20). - NIP and ODS products are projected to contribute significantly, potentially reaching 30%-40% of overall business in the next 2-3 years (Pages 13, 16). - European and regulated market rollout of NIP products expected from FY'25, likely driving strong revenue growth (Pages 16, 21). - Volume growth in FY'25 and FY'26 is anticipated as new product filings mature and approvals come through (Pages 12, 16). - Capacity expansion aims to double output in the next two years, supporting revenue growth (Page 7, 8). - Currency issues impacting short-term revenue but expected to ease, supporting recovery in earnings (Page 19). - Order pipeline and out-licensing fees growing, indicating rising commercial traction ahead (Page 8). Overall, earnings growth is expected driven by NIP product traction, capacity expansion, and entry into regulated markets with improved margins.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company is focused on CapEx investments, with a Rs. 25 Crore CapEx planned for the next quarter and ongoing investments based on regulatory and strategic requirements.
→CapEx decisions beyond the ongoing investments will be made post-audit, indicating no immediate new fundraising plans.
→The discussion also highlights internal funding of expansion and R&D activities without reference to raising external capital.
→Overall, the company appears to be managing funded growth through operational cash flows and planned CapEx, with no indication of imminent debt or equity fundraising.

Order book

→There is a robust order list for Nutraceutical products, with several orders in hand.
→Some supply is pending due to currency issues in certain markets, as supplies are against advance payments.
→A single Nutra order from last year, worth about Rs. 20 crores, was not repeated due to currency constraints.
→The business saw a revenue loss of approximately Rs. 20 crores last year linked to currency issues.
→Supply has started for filings done in regulated markets, with agreements made and orders flowing in.
→NIP and ODS product orders have started contributing to business, with strong growth expected in FY25.
→More order inflows from European and regulated markets are anticipated as MA approvals come through in 1.5 to 2 years post-filing.

Capex plans

Yes

→Anwar Daud and Shyam Patro mentioned ongoing and future CapEx investments aligned with regulatory needs and strategic expansion.
→Next quarter CapEx investment expected around Rs. 25 Crore.
→CapEx is focused on debottlenecking, capacity expansion, and regulatory compliance, including preparations for ANVISA inspections in South American markets like Brazil and Mexico.
→There is a plan to double overall capacity in the next two years, with a 25% to 40% capacity enhancement expected in the coming couple of years.
→Additional CapEx decisions will be made post-audit based on future requirements.
→CapEx supports the rollout and scaling of new innovative products (NIPs) and Oral Thin Film (OTF) technologies.
→The investment aims to position ZIM for growth in regulated markets (Europe, Brazil, Mexico, Southeast Asia) and support regulatory filings and approvals.
→CapEx spending aligns with strategy to improve R&D and market compliance.

How does Zim Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Zim Laboratories Ltd

Rev 2Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Zim Laboratories Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio